Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Adir Shaulov, Irit Avivi, Yael Cohen, Adrian Duek, Merav Leiba & Moshe E. Gatt. (2018) Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy – a case series and review of the literature. Amyloid 25:1, pages 11-17.
Read now
Read now
Florine Obrist, Gwenola Manic, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2015) Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology 2:2.
Read now
Read now
Arvind Kumar, Mayur Porwal, Ankita Verma & Arun K. Mishra. (2014) Impact of pomalidomide therapy in multiple myeloma: a recent survey. Journal of Chemotherapy 26:6, pages 321-327.
Read now
Read now
Mieke WH Roeven, Willemijn Hobo, Nicolaas Schaap & Harry Dolstra. (2014) Immunotherapeutic approaches to treat multiple myeloma. Human Vaccines & Immunotherapeutics 10:4, pages 896-910.
Read now
Read now
Articles from other publishers (33)
Raushanara Akter, Md. Rashidur Rahman, Zainab Syed Ahmed & Afrina Afrose. (2023) Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations. Heliyon 9:6, pages e17478.
Crossref
Crossref
Rinki Kumari, Anita Venaik, Jasmeet Singh & Rajesh K. Kesharwani. 2022. Immunomodulators and Human Health. Immunomodulators and Human Health
349
367
.
Arshia Soleimani, Madhurima Koka, Zeba N. Singh, Vivek Kesari & Ashraf Badros. (2020) Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax. Clinical Lymphoma Myeloma and Leukemia 20:9, pages e556-e559.
Crossref
Crossref
Fehaid Alanazi, Faith A.A. Kwa, Genia Burchall & Denise E. Jackson. (2020) New generation drugs for treatment of multiple myeloma. Drug Discovery Today 25:2, pages 367-379.
Crossref
Crossref
Ugonma N. Chukwueke, Eudocia Q. Lee & Patrick Y. Wen. 2020. Central Nervous System Metastases. Central Nervous System Metastases
365
372
.
Pilar Guerra‐García, Lynley V. Marshall, Julia V. Cockle, Purushotham V. Ramachandran, Frank H. Saran, Chris Jones & Fernando Carceller. (2019) Challenging the indiscriminate use of temozolomide in pediatric high‐grade gliomas: A review of past, current, and emerging therapies. Pediatric Blood & Cancer 67:1.
Crossref
Crossref
Tomohiro Umezu, Satoshi ImanishiSeiichiro YoshizawaChiaki KawanaJunko H. Ohyashiki & Kazuma Ohyashiki. (2019) Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion. Blood Advances 3:21, pages 3228-3240.
Crossref
Crossref
Ibrahim Jantan, Md. Areeful Haque, Menaga Ilangkovan & Laiba Arshad. (2019) An Insight Into the Modulatory Effects and Mechanisms of Action of Phyllanthus Species and Their Bioactive Metabolites on the Immune System. Frontiers in Pharmacology 10.
Crossref
Crossref
Xiaohong Xia, Yuan Liu, Yuning Liao, Zhiqiang Guo, Chuyi Huang, Fangcheng Zhang, Lili Jiang, Xuejun Wang, Jinbao Liu & Hongbiao Huang. (2019) Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC. European Journal of Pharmacology 856, pages 172409.
Crossref
Crossref
Dávid Vrábel, Luděk Pour & Sabina Ševčíková. (2019) The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Reviews 34, pages 56-66.
Crossref
Crossref
Xinwei Yang, Xiyun Zhao & Xiaoxia Wang. (2019) Compound kushen injection for multiple myeloma. Medicine 98:50, pages e18257.
Crossref
Crossref
Shougang Sun, Quan Zhang, Qiongying Wang, Qiang Wu, Guangli Xu, Peng Chang, Hao Hu & Feng Bai. (2018) Local delivery of thalidomide to inhibit neointima formation in rat model with artery injury. Pathology - Research and Practice 214:9, pages 1303-1308.
Crossref
Crossref
Øyvind Bruserud, Bent-Are Hansen, Nils Vetti, Silje Johansen & Håkon Reikvam. (2018) Successful eradication of leptomeningeal plasma cell disease. Oxford Medical Case Reports 2018:7.
Crossref
Crossref
Deborah A. Forst & Patrick Y. Wen. 2018. Cancer Neurology in Clinical Practice. Cancer Neurology in Clinical Practice
311
333
.
Brian J. North, Ingrid Almeciga-Pinto, David Tamang, Min Yang, Simon S. Jones & Steven N. Quayle. (2017) Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor. PLOS ONE 12:3, pages e0173507.
Crossref
Crossref
Yusuke Yamashita, Shinobu Tamura, Takehiro Oiwa, Hiroshi Kobata, Kodai Kuriyama, Toshiki Mushino, Shogo Murata, Hiroki Hosoi, Akinori Nishikawa, Nobuyoshi Hanaoka & Takashi Sonoki. (2017) Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient. Hematology Reports 9:1, pages 28-31.
Crossref
Crossref
Jonghoon Park, Eok Park, Cheol-Kyu Jung, Seung-Wan Kang, Byung Gyu Kim, Youngjoo Jung, Tae Hun Kim, Ji-Young Lim, Sung-Eun Lee, Chang-Ki Min & Kwang-Ai Won. (2016) Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer 16:1.
Crossref
Crossref
Yuying LiZhonghua DuXu WangGuanjun WangWei Li. (2016)
Association of
IL-6
Promoter and Receptor Polymorphisms with Multiple Myeloma Risk: A Systematic Review and Meta-Analysis
. Genetic Testing and Molecular Biomarkers 20:10, pages 587-596.
Crossref
Crossref
SABNA RAJEEV KRISHNAN, RITU JAISWAL, ROSS D. BROWN, FREDERICK LUK & MARY BEBAWY. (2016) Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). International Journal of Oncology 49:1, pages 33-50.
Crossref
Crossref
Xiaoxue Wang, Yan Li & Xiaojing Yan. (2016) Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. BioMed Research International 2016, pages 1-17.
Crossref
Crossref
YEN TA HUANG, CHUAN CHU CHENG, TED H. CHIU & PEI CHUN LAI. (2015) Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. International Journal of Oncology 47:5, pages 1711-1724.
Crossref
Crossref
Shuhui Deng, Yan Xu, Gang An, Weiwei Sui, Dehui Zou, Yaozhong Zhao, Junyuan Qi, Fei Li, Mu Hao & Lugui Qiu. (2015) Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases. Clinical Lymphoma Myeloma and Leukemia 15:5, pages 286-291.
Crossref
Crossref
Gustav J. Ullenhag, Eva Rossmann & Maria Liljefors. (2015) A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLOS ONE 10:4, pages e0121197.
Crossref
Crossref
Urmeel H. Patel, Muhammad A. Mir, Jeffrey K. Sivik, Divisha Raheja, Manoj K. Pandey & Giampaolo Talamo. (2015) Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma. Hematology Reports 7:1, pages 5704.
Crossref
Crossref
Ali McBride, Jeff O. Klaus & Keith Stockerl-Goldstein. (2015) Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma. American Journal of Health-System Pharmacy 72:5, pages 353-360.
Crossref
Crossref
J Bae, R Prabhala, A Voskertchian, A Brown, C Maguire, P Richardson, G Dranoff, K C Anderson & N C Munshi. (2014) A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 29:1, pages 218-229.
Crossref
Crossref
Lesley J. Scott. (2014) Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma. Drugs 74:5, pages 549-562.
Crossref
Crossref
M.M. Picken. 2014. Pathobiology of Human Disease. Pathobiology of Human Disease
2831
2852
.
Robert Z. Orlowski. (2013) Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials. Seminars in Oncology 40:5, pages 634-651.
Crossref
Crossref
Chris Mahony, Lynda Erskine, Jennifer NivenNigel H. Greig, William Douglas Figg & Neil Vargesson. (2013) Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proceedings of the National Academy of Sciences 110:31, pages 12703-12708.
Crossref
Crossref
V Sardnal, A Rouquette, S Kaltenbach, C Bally, V Chesnais, C Leschi, L Ades, V Santini, S Park, A Toma, P Fenaux, F Dreyfus, M Fontenay & O Kosmider. (2013) A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia 27:7, pages 1610-1613.
Crossref
Crossref
Fabrizio Vinante & Antonella Rigo. (2013) Heparin-Binding Epidermal Growth Factor-like Growth Factor/Diphtheria Toxin Receptor in Normal and Neoplastic Hematopoiesis. Toxins 5:6, pages 1180-1201.
Crossref
Crossref
Shelley Elkinson & Paul L. McCormack. (2013) Pomalidomide: First Global Approval. Drugs 73:6, pages 595-604.
Crossref
Crossref